Gene therapy for cancer: what have we done and where are we going?
about
Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status.Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategiesBiochemical and structural characterization of (South)-methanocarbathymidine that specifically inhibits growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cellsAnti-tumor effect of hematopoietic cells carrying the gene of ribonuclease inhibitorLearning therapeutic lessons from metastasis suppressor proteins.Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen.Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas.Cytochrome P450-based cancer gene therapy: recent advances and future prospects.Infection control in gene therapy.Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapyHigh-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments.Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease.Replication-selective adenoviruses as oncolytic agents.Immunomodulation of cancer: potential use of selectively replicating agents.Progress with retroviral gene vectors.Prodrug activation enzymes in cancer gene therapy.Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies.Gene therapy in human cancer: report of human clinical trials.Infection control for gene therapy: a busy physician's primer.Gene therapy: development of immunostimulatory treatments for cancer.AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis modelOncolytic viruses as therapeutic agents.Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction.Cancer gene therapy clinical trials: lessons for the future.Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal speciesHead and neck cancer: gene therapy approaches. Part II: genes delivered.Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.Clinical impact of novel treatment strategies.CXCL16 suppresses liver metastasis of colorectal cancer by promoting TNF-α-induced apoptosis by tumor-associated macrophages.A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha.Intravascular adenoviral agents in cancer patients: lessons from clinical trials.Progress and limitations in cancer gene therapy.INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?Tumor-specific gene expression using the survivin promoter is further increased by hypoxiaInhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy.Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma.Characterization of nanoparticle mediated laser transfection by femtosecond laser pulses for applications in molecular medicine.
P2860
Q24542478-9ADEA75E-A853-4D2E-9B12-AD43361DFC6AQ24797891-A32AFA1C-440B-4148-BA30-207CF6252024Q28263579-16C83269-44BE-46A0-8393-E8DBD791BAC1Q28297894-19762124-C7F1-4F9B-82F4-57B3F85AC0F9Q30435922-DF998C1F-E2C7-40B7-8AA0-F22B19450C7CQ30715508-022F90A6-19BA-4124-AC7E-68446FFC133EQ33181472-7BB8A66D-8233-4CA7-A388-9EB91FB810D4Q33639790-F3D43692-6A3E-4D57-B04D-983006526F10Q33722265-C35C886F-FCE4-417B-BD0E-4099776E963BQ33731187-EF95C290-9BED-4C93-92D9-1CEDA92488AEQ33784122-64E4E264-91CA-4EBC-B6B0-E0C9CB1181DBQ33846198-7D33AE6B-3469-4182-8F5A-4358136A9930Q33882702-DBE192A5-9781-4624-BC70-10E6F36DB9DAQ33904276-90477ACE-C8B6-4D2C-8367-79051A4C25CAQ33920752-13444F1E-B982-4116-8EC5-FE368C2CBAC0Q33968115-E6914FED-DECD-4A33-BF30-79418A61960EQ34063131-E479FDEA-973F-4945-83F3-033BB6B93B1CQ34099395-44B8CA63-26A3-4D0B-AF27-82C947CF86C8Q34144013-BA170C2D-A124-4C70-A254-D85D1885C448Q34187915-0B2FFBFB-4F70-456D-8640-FC922F30182AQ34214323-C7633F36-C940-4659-A86E-6E6FDC7EB801Q34329548-5D661553-AC8E-45F5-A6E7-DDC7619E64C7Q34415371-27DC5893-A637-41E0-9D03-514117640EB8Q34433429-FFCA7A7F-0B7C-4CE9-9B63-2449AA1A876BQ34447184-81166A96-2237-4376-9CBA-BA97FE70556CQ34545667-24363C08-90E7-4845-BD31-D7F159CED072Q34560682-12B04565-EA24-4B05-B374-4065048B0B94Q34790267-40BA456F-0A24-4CFE-B2FA-7B2E27715459Q34936052-10475210-11EE-4D3A-AA24-CB161E1D07DCQ34990965-CFFAA820-3854-492E-A7FA-9F16287B67D3Q35000575-99342253-CE78-4A2F-8D80-9FF8CEF0903DQ35043094-C96D54E2-AEE4-423F-918D-D14DB8BE8143Q35051969-A61C0760-E44C-4851-85D4-FC200F00D1A1Q35136043-F037C317-A869-494F-A3C5-53AF38F6E4D4Q35142325-6B238A97-9D3C-4572-9A82-988B6449E7E8Q35142329-515F82FF-F0F5-4A42-BBCA-A794C36168B4Q35184871-B8C59C26-C708-4FB6-9F41-1AA1B9235C50Q35193397-C7783CB9-1700-455D-84E2-24F4D7AF0BF5Q35308393-23D56036-95EC-4133-AFCA-89626DF03A79Q35553960-E6400853-B2FF-47E8-8D93-8CFEDBF1505D
P2860
Gene therapy for cancer: what have we done and where are we going?
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Gene therapy for cancer: what have we done and where are we going?
@en
type
label
Gene therapy for cancer: what have we done and where are we going?
@en
prefLabel
Gene therapy for cancer: what have we done and where are we going?
@en
P2860
P356
P1476
Gene therapy for cancer: what have we done and where are we going?
@en
P2093
P2860
P356
10.1093/JNCI/89.1.21
P407
P577
1997-01-01T00:00:00Z